Are recent strides in neurology R&D enough to make it a hot M&A target?news2025-10-23T14:00:48+00:00October 23rd, 2025|Endpoints News|
Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?news2025-10-16T14:47:42+00:00October 16th, 2025|Endpoints News|
Chinese biotechs work on cheaper alternatives to $2M Zolgensmanews2025-10-09T14:00:08+00:00October 9th, 2025|Endpoints News|
In the Lab: How Amgen sees AI changing pharma R&Dnews2025-10-08T14:00:50+00:00October 8th, 2025|Endpoints News|
Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite lossnews2025-08-28T11:00:44+00:00August 28th, 2025|Endpoints News|
Prader-Willi syndrome is not a zero-sum game. There’s room for many winnersnews2025-08-21T11:00:48+00:00August 21st, 2025|Endpoints News|
Pharma’s IRA fight persists as it looks to Supreme Court, lobbies for changesnews2025-08-14T18:55:18+00:00August 14th, 2025|Endpoints News|
In the scramble for capital, biotechs turn to royalty dealsnews2025-08-14T15:11:39+00:00August 14th, 2025|Endpoints News|
The future of ICHRA hinges on a market in meltdownnews2025-08-12T13:00:46+00:00August 12th, 2025|Endpoints News|
FDA’s continued approval of mRNA shots is infuriating some in MAHAnews2025-07-21T18:29:22+00:00July 21st, 2025|Endpoints News|
